Hansoh Pharma Ranked in Top 1% in S&P Global's Inaugural Sustainability Yearbook (China Edition) with Significant ESG Leadership

Recently, Hansoh Pharma was selected for the first-ever "Sustainability Yearbook (China Edition)" published by S&P Global. With a significantly leading ESG score, it ranked among the top 1% in the industry and received the honor of "Industry Best Progress Enterprise."

According to the yearbook selection rules, these two achievements mark that Hansoh Pharma's 2022 CSA score (63 points) ranked first in China's pharmaceutical industry and showed the largest improvement in the industry. Previously, Hansoh Pharma had successfully been selected for S&P's "Sustainability Yearbook" (Global Edition), becoming the only company from mainland China's pharmaceutical industry to be included.

The S&P CSA, initiated by S&P Global, is one of the largest annual assessments of corporate sustainability practices worldwide. As global stakeholders continue to deepen their focus on ESG, the influence of the S&P CSA is rapidly expanding both in China and internationally.

In 2022, the number of companies worldwide participating in CSA reached a record high. Hansoh Pharma stood out among more than 1,600 Chinese enterprises with its outstanding sustainability performance, earning high recognition from international authorities.

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. The company continuously improves its policies and systems, enhancing its ESG management system, which includes governance structure and strategy, product safety and quality, human resources and development, climate action and low-carbon environmental protection, and social responsibility, to build long-term momentum for the company's global innovative development. (Zhu Wen)